Ocular Therapeutix has randomized the first patient in HELIOS-3, the second of two Phase 3 registrational trials evaluating AXPAXLI (also known as OTX-TKI) for non-proliferative diabetic retinopathy (NPDR). The HELIOS program features complementary superiority studies: HELIOS-2 compares AXPAXLI dosed every 12 months to ranibizumab 0.3 mg, while HELIOS-3 tests 6- and 12-month AXPAXLI regimens versus sham. Both use a novel ordinal ≥2-step change in Diabetic Retinopathy Severity Scale (DRSS) as the primary endpoint at 52 weeks. HELIOS-2 operates under an FDA Special Protocol Assessment aligning on the endpoint, and both studies include patients with non–center-involved diabetic macular edema to target a broader diabetic retinopathy label.
The strategic bet is clear: move DR care upstream with a durable, low-frequency intervention that can shift the natural history of disease before vision-threatening events occur. If AXPAXLI can deliver clinically meaningful, once- or twice-yearly efficacy, it challenges the inertia that has kept fewer than 1% of 6.4 million U.S. NPDR patients on therapy despite existing anti-VEGF options. The pivotal question for commercial and medical leaders is whether early, preventive treatment—supported by an endpoint that captures improvement, stability, and worsening—can overcome entrenched patterns of watchful waiting and payer reluctance to reimburse asymptomatic patients.
This matters now because NPDR prevalence is rising in lockstep with diabetes, retina clinics are capacity constrained, and the field’s push toward durability has not fully solved the treatment-burden barrier. Long-acting anti-VEGF regimens have extended intervals to 12–16 weeks in DR and DME, but annual dosing would be a step change in convenience. For patients, particularly working-age adults who struggle to adhere to frequent office visits, a bioresorbable axitinib hydrogel administered once or twice a year could reduce progression to proliferative disease and lower the risk of irreversible vision loss. For payers, the calculus hinges on hard outcomes: fewer conversions to proliferative DR, reduced need for rescue therapy, and downstream cost offsets that justify earlier intervention. Medical Affairs teams will need to translate the ordinal DRSS effect into outcomes that resonate with coverage committees, including progression rates, treatment-free intervals, and quality-of-life metrics in real-world settings.
Competitive dynamics are intensifying across retina. Incumbent biologics have broadened DR labels and pushed dosing intervals, while new modalities—from sustained-delivery platforms to TKIs—are competing on durability, procedure burden, and practice economics. AXPAXLI’s mechanism and delivery profile position it against both anti-VEGF mainstays and emerging long-acting TKIs, with the potential to redefine treatment thresholds if superiority is demonstrated. The decision to include non–center-involved DME and to deploy an ordinal endpoint reflects a wider regulatory and methodological shift toward measures that better mirror clinical goals and enable more efficient trials. That alignment, combined with the scale of the untreated NPDR population, sets the stage for a market access conversation that could reshape how payers view prophylactic retina treatment.
The next test is execution and evidence. With 52-week primary readouts, the program must deliver superiority that translates into payer-relevant outcomes and practice-level advantages. If successful, will annual intravitreal TKIs trigger a wholesale pivot to earlier NPDR treatment, or will incumbents defend share through outcomes-based contracts, pricing moves, and expanded extended-interval data?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
